Ibnsina Pharma Valuation

Q: What is the Fair Price of ISPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ISPH (EGP5.39) is trading below our estimate of [[fair value]] (EGP8.56)

Is ISPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ISPH (EGP5.39) is trading below our estimate of fair value (EGP8.56)

Significantly Below Fair Value: ISPH is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISPH?

Key metric: As ISPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ISPH. This is calculated by dividing ISPH's market cap by their current earnings.
What is ISPH's PE Ratio?
PE Ratio	15x
Earnings	ج.م361.37m
Market Cap	ج.م5.43b

ISPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	11x
PEG Ratio	0.3x

Price to Earnings Ratio vs Peers

How does ISPH's PE Ratio compare to its peers?

The above table shows the PE ratio for ISPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	14.7x
CLHO Cleopatra Hospitals GroupE	25.2x	30.9%	ج.م11.4b
NINH Nozha International Hospital	16.5x	n/a	ج.م1.9b
SFT Sopharma Trading AD	5.7x	n/a	лв198.8m
7600 Japan Medical Dynamic Marketing	11.6x	14.9%	JP¥16.3b
ISPH Ibnsina Pharma	15x	43.2%	ج.م5.4b

Price-To-Earnings vs Peers: ISPH is expensive based on its Price-To-Earnings Ratio (15x) compared to the peer average (14.7x).

Price to Earnings Ratio vs Industry

How does ISPH's PE Ratio compare vs other companies in the Global Healthcare Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ISPH is good value based on its Price-To-Earnings Ratio (15x) compared to the Global Healthcare industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is ISPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15x
Fair PE Ratio	24.7x

Price-To-Earnings vs Fair Ratio: ISPH is good value based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (24.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ISPH forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	ج.م5.39	ج.م6.76 +25.3%	28.6%	ج.م9.10	ج.م4.12	n/a	4
Nov ’25	ج.م5.20	ج.م6.34 +21.9%	32.6%	ج.م9.10	ج.م4.12	n/a	3
Oct ’25	ج.م5.25	ج.م4.96 -5.5%	16.9%	ج.م5.80	ج.م4.12	n/a	2
Sep ’25	ج.م3.37	ج.م4.84 +43.6%	14.6%	ج.م5.80	ج.م4.12	n/a	3
Aug ’25	ج.م2.95	ج.م4.84 +64.2%	14.5%	ج.م5.80	ج.م4.13	n/a	3
Jul ’25	ج.م2.93	ج.م4.84 +65.3%	14.5%	ج.م5.80	ج.م4.13	n/a	3
Jun ’25	ج.م2.62	ج.م4.63 +76.8%	15.3%	ج.م5.80	ج.م4.00	n/a	4
May ’25	ج.م2.43	ج.م4.63 +90.6%	15.3%	ج.م5.80	ج.م4.00	n/a	4
Apr ’25	ج.م2.50	ج.م4.63 +85.3%	15.3%	ج.م5.80	ج.م4.00	n/a	4
Mar ’25	ج.م3.80	ج.م4.63 +21.8%	15.4%	ج.م5.80	ج.م4.00	n/a	4
Feb ’25	ج.م3.00	ج.م3.43 +14.3%	24.7%	ج.م4.12	ج.م2.00	n/a	4
Jan ’25	ج.م3.14	ج.م3.43 +9.2%	24.7%	ج.م4.12	ج.م2.00	n/a	4
Dec ’24	ج.م2.70	ج.م3.43 +27.0%	24.7%	ج.م4.12	ج.م2.00	n/a	4
Nov ’24	ج.م2.44	ج.م2.95 +20.9%	30.1%	ج.م4.00	ج.م1.80	ج.م5.20	4
Oct ’24	ج.م1.97	ج.م2.60 +31.9%	28.8%	ج.م3.60	ج.م1.80	ج.م5.25	3
Sep ’24	ج.م2.09	ج.م2.36 +12.9%	18.7%	ج.م2.88	ج.م1.80	ج.م3.37	3
Aug ’24	ج.م2.17	ج.م2.36 +8.8%	18.7%	ج.م2.88	ج.م1.80	ج.م2.95	3
Jul ’24	ج.م2.59	ج.م2.36 -8.9%	18.7%	ج.م2.88	ج.م1.80	ج.م2.93	3
Jun ’24	ج.م2.21	ج.م2.36 +6.8%	18.7%	ج.م2.88	ج.م1.80	ج.م2.62	3
May ’24	ج.م1.65	ج.م3.45 +109.5%	63.1%	ج.م7.67	ج.م1.80	ج.م2.43	5
Apr ’24	ج.م1.37	ج.م3.45 +152.7%	63.1%	ج.م7.67	ج.م1.80	ج.م2.50	5
Mar ’24	ج.م1.69	ج.م3.75 +121.5%	56.5%	ج.م7.67	ج.م1.80	ج.م3.80	5
Feb ’24	ج.م1.79	ج.م4.41 +146.5%	43.3%	ج.م7.67	ج.م2.00	ج.م3.00	5
Jan ’24	ج.م2.16	ج.م4.00 +85.0%	49.6%	ج.م7.67	ج.م1.90	ج.م3.14	6
Dec ’23	ج.م1.93	ج.م4.00 +106.8%	49.6%	ج.م7.67	ج.م1.90	ج.م2.70	6
Nov ’23	ج.م1.83	ج.م4.59 +150.3%	40.9%	ج.م7.67	ج.م1.90	ج.م2.44	5

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.